Calendar of Events
S Sun
M Mon
T Tue
W Wed
T Thu
F Fri
S Sat
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
1 event,
Pre-Filled Syringes and Injectable Drug Devices Europe
SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below:
• Novel Drug Products and Large Volume Delivery
• Sustainability for Injectable Delivery Devices
• Primary Packaging Development
• Connected Drug Delivery Devices
0 events,
0 events,
1 event,
PepTalk: The Protein Science and Production Week
PepTalk connects protein science researchers from around the globe to share case studies, unpublished data, breakthroughs, and solutions that support and enhance biotherapeutics R&D.
This year’s event will feature world-renowned speakers, cutting-edge technologies, and engaging networking events. Programming includes in-depth coverage of antibody discovery, protein engineering, bispecific antibodies, emerging immunotherapies, protein aggregation, machine learning, cell and gene therapy, protein expression, purification and production.
0 events,
1 event,
2nd annual Transdermal and Microneedle Drug Delivery Conference
SAE’s 2nd annual Transdermal and Microneedle Drug Delivery conference will explore advances in microneedle diagnostics through case studies and real-world examples, whilst engaging in modern strategies for topical and transdermal drug delivery. The two-day agenda offers you peer-to-peer networking with CEO’s, Senior Vice presidents, Directors of Delivery Technologies, Heads of Product Development and many more.
Key considerations for the conference will be transdermal and microneedle systems as a mode of therapeutic drug delivery in combination with optimization of device design and development. Vaccine delivery will a significant aspect of this year’s agenda with a focus on microneedle delivery technologies as a mode for vaccine delivery, in the pursuit to increase vaccine stability and accessibility. An outlook of the transdermal space will also be reviewed, including future directions and next steps required to advance the current field and accelerate access for patients and end users.
2 events,
Next Generation Ophthalmic Drug Delivery Summit
The inaugural Next Generation Ophthalmic Drug Delivery Summit is coming to San Francisco in January 2023, to help ophthalmic drug developers overcome translational challenges of developing novel long-lasting ophthalmic therapies via novel delivery methods to reduce healthcare burden and increase patient compliance.
Join 21+ expert speakers from the likes of Genentech, Aerie Pharmaceuticals, Novartis, Clearside Biomedical, Janssen, Eyevensys, and EyePoint Pharmaceuticals to overcome your translational challenges and enhance extended drug efficacy while avoiding systemic and local adverse effects. Don’t miss your only opportunity for an industry-specific meeting for networking and sharing extended-duration therapies with the ophthalmic drug development community.
3 events,
The Festival of Genomics & Biodata
WELCOME BACK to the annual get-together for the entire genomics and biodata community, to discover, meet, learn and celebrate! This year's Festival will bring you inspirational speakers, the latest research and clinical breakthroughs, cutting-edge technology and incredible networking opportunities.
Free for 90% of attendees, the Festival is designed to help you return to work armed with dozens of new ideas and contacts, but also to keep you engaged, excited and proud of the difference your efforts make for patients.
We can't wait to welcome you back in-person, for what promises to be our largest in-person and most vibrant Festival yet. Explore this year's agenda and speakers, find out what activities are taking place, and don't forget to register early as tickets are limited.
0 events,
0 events,
2 events,
3rd TGF-β for Immuno-Oncology Drug Development Summit
In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine.
From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.
Tailored with 18+ senior leaders, the 2023 meeting will be taking place in-person for the first time - don't miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!
Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.
2nd Allogeneic Cell Therapies Summit Europe
Allogeneic approaches are deemed the future of cell therapy due to their potential to reduce costs, increase accessibility and enhance availability. However as clinical readouts emerge, challenges associated with limited durability, solid tumour targeting and therapy immunogenicity are hindering their efficacies.
The Allogeneic Cell Therapies Summit Europe is returning in January to capture the clinical advances of European drug developers whilst addressing the specific challenges they face in development. These include European regulatory affairs, donor selection, scalable manufacturing and therapy persistence.
With continued investment and growth in the allogeneic space, join European leaders from Gadeta, Antion Biosciences, TC BioPharm, and many more, as well as the US leaders undertaking European trials. This includes Atara Bio and Adicet Bio, as they progress development of multiple cell types to produce the next-generation of safe, effective and accessible cell therapies in Europe.
3 events,
Viral Vector Process Development Summit
As cell & gene therapy and genomic medicine pipeline continues to mature, process development for viral vector is becoming critical for drug developers for the next phase, to deliver a quality, transformative cure to patients with affordability. The recent investments such as Novartis-Samsung Biologics $81m contract for viral vector manufacturing, Resilience raising $625m towards biomanufacturing capabilities including stable cell lines for viral vector production pave the foundation for scientific and technology innovations.
With better understanding of these novel nanoparticles, developability and cell line development, the ability to optimize AAV, LV formulation and define robust CQAs are critical to drug developers’ ability to increase scalability with efficiency, reduce cost of goods and most importantly, ensure product quality control for patients.